BioMarin Pharmaceutical Inc. has named Cristin Hubbard as executive vice president and chief commercial officer.
 
Hubbard will assume responsibility for the company’s global commercial operations, effective May 20, succeeding Jeff Ajer.

Experience

Hubbard has more than 20 years of experience in the biopharmaceutical and diagnostics industries. She served most recently as the head of Global Product Strategy for Roche Pharma, where she was responsible for lifecycle management, accelerating delivery of the company’s medicines from development to commercialization, across five therapeutic areas. She was also accountable for delivering portfolio prioritization and integrated strategic plans across the company’s entire portfolio.
 
Prior to that, she served as global head of Diagnostics Partnering for Roche Diagnostics, with responsibility for driving growth through licensing deals and acquisitions. Over more than 16 years at Roche and Genentech, she served in a number of senior roles across therapeutic areas, including immunology, infectious disease, oncology, ophthalmology and hemophilia. She brings significant expertise and leadership experience in both launching and growing successful new medicines.
 
Hubbard started her career as a medicinal chemist at Theravance, before joining Roche and Genentech.
 
She holds a bachelor’s degree in Biochemistry and Molecular Biology from the University of California, Santa Cruz. She also completed the Graduate Program of Health Management at the University of California, Berkeley, earning an MBA from the Haas School of Business and an MPH from the School of Public Health.
 
“I am confident that Cristin is the right leader for our commercial organization as BioMarin enters this next chapter, bringing to the company expertise in lifecycle management and a strong track record of delivering growth across multiple therapeutic areas, successfully advancing programs from development to commercialization across a broad portfolio,” said Alexander Hardy, president and chief executive officer of BioMarin. “Her deep experience in the biopharmaceutical industry will add to the great talent I have seen across the organization since joining several months ago. We look forward to welcoming her to BioMarin and to the important work we will do together for patients.”
 
“Throughout my career, I’ve seen firsthand the important role that medicines and diagnostics play in the prevention, treatment and management of serious diseases,” said Hubbard. “BioMarin has made incredible progress in transforming care for patients with serious medical conditions over the past two decades and I look forward to working with the team to increase that impact with the current portfolio and new product candidates.”

More BioMarin News

Last year, the U.S. FDA approved BioMarin Pharmaceutical Inc.’s Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test.